Abstracts tagged "RCT and scleroderma"

Abstract Number: 2999 • 2014 ACR/ARHP Annual Meeting
Development of a Composite Index for Clinical Trials in Early Diffuse Cutaneous Systemic sclerosis—the Combined Response Index in Systemic Sclerosis
Dinesh Khanna¹, Veronica Berrocal², Edward Giannini³, Maureen Mayes⁴, Peter A. Merkel⁵, Jeffrey Siegel⁶, James R. Seibold⁷, Murray Baron⁸, Philip J. Clements⁹, Yannick Allanore¹⁰, Virginia D. Steen¹¹, Christopher P. Denton¹², Oliver Distler¹³, Sindhu R. Johnson¹⁴, Marco Matucci-Cerinic¹⁵, Lazlo Czirjak¹⁶, Janet E. Pope¹⁷, Susanna Proudman¹⁸, Weng Kee Wong¹⁹, Athol U. Wells²⁰ and Daniel E. Furst⁹, ¹University of Michigan Scleroderma Program, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Ped Rheum/Pav 2-129, Childrens Hosp Med Ctr, Cincinnati, OH, ⁴Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX, ⁵Vasculitis Center, E5, Boston University School of Medicine, Boston, MA, ⁶Genentech, South San Francisco, CA, ⁷Scleroderma Research Consultants LLC, Avon, CT, ⁸Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁹University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ¹⁰Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ¹¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹²Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom, ¹³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹⁴Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ¹⁶Immunology and Rheumatology, University of Pécs, Pécs, Hungary, ¹⁷Medicine, Western University, London, ON, Canada, ¹⁸Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹⁹Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, ²⁰Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a multisystem disease that involves skin and internal organs. Our objective was to develop a composite response index in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].